UniPharma Co., Ltd. engages in the distribution of pharmaceutical drugs, medical devices, and diagnostic tests in Taiwan. It provides diagnostic tests in areas of oncology, gynecology, orthopedics, neurology, anesthesiology, and cardiology. The company offers Adept reduction solution; bain, esmolol HCI, and naloxone anesthesia injections; Elisa DR-70 test for in-vitro diagnostics of tumors; and fomeject antidote injection, as well as drug development, research and development, clinical trials, marketing, and other business services. It serves medical centers, regional and area hospitals, and clinics. UniPharma Co., Ltd. was founded in 1998 and is based in Taipei, Taiwan.
Frequently asked questions
What sector does UniPharma Co., Ltd. (6621) operate in?
UniPharma Co., Ltd. belongs to the Other sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is UniPharma Co., Ltd. (6621) current stock price?
As of the latest data, UniPharma Co., Ltd. stock price is NT$11.50, with a previous close of NT$11.50.
What is UniPharma Co., Ltd. (6621) current market capitalization?
UniPharma Co., Ltd. market cap is approximately 414.44 million.
What is UniPharma Co., Ltd. (6621) Earnings Per Share (EPS)?
The trailing EPS is -NT$1.14.
Does UniPharma Co., Ltd. (6621) pay dividends?
No. UniPharma Co., Ltd. does not pay a dividend.
What is UniPharma Co., Ltd. (6621) beta (volatility) score?
UniPharma Co., Ltd. has a beta of -0.207, indicating lower volatility than the overall market.
